natgillin/translations-raw huggingface dataset:
Before you are given this medicine your doctor needs to know :
Preden boste prejeli to zdravilo, morate obvestiti zdravnika:
The frequency of some side effects is not known (events from spontaneous reports and the frequency cannot be estimated from the available data):
Za nekatere neželene učinke pogostnost ni znana (podatki o njih izhajajo iz spontanih poročil, tako da njihove pogostnosti ni mogoče ugotoviti iz razpoložljivih podatkov):
The dose of topotecan you are given will be worked out by your doctor, based on:
Odmerek topotekana, ki ga boste prejeli, bo zdravnik določil na podlagi:
If not used immediately, Topotecan Hospira can be used for up to 24 hours when stored in the fridge (protected from light) or at room temperature (in normal daylight conditions).
Če ni uporabljeno takoj, lahko zdravilo Topotecan Hospira uporabljate še največ 24 ur, če ga shranjujete v hladilniku (zaščitenega pred svetlobo) ali pri sobni temperaturi (v pogojih normalne dnevne svetlobe).
Topotecan Hospira helps to destroy tumours.
Topotecan Hospira pomaga uničevati tumorje.
The pharmacokinetics of topotecan given as a 30-minute infusion for 5 days were evaluated in two studies.
Farmakokinetiko topotekana, danega v obliki 30-minutne infuzije v času 5 dni, so ovrednotili v dveh študijah.
Of the patients who received more than 6 cycles of therapy, 91 % completed the study as planned or were treated until disease progression, with only 3 % withdrawn for adverse events.
Od bolnic, ki so bile deležne več kot šest ciklov zdravljenja, jih je 91 % dokončalo raziskavo kot je bilo predvideno, ali pa so jih zdravili, dokler je bila bolezen v progresiji.
• the disease being treated.
• bolezni, zaradi katere se zdravite.
Do not restart breast-feeding until the doctor tells you it is safe to do so.
Z dojenjem tudi ne smete ponovno začeti, dokler vam zdravnik ne pove, da je to varno.
Topotecan half-life was increased by about 30 % but no clear change in volume of distribution was observed.
Razpolovna doba topotekana se je podaljšala za približno 30 %, medtem ko jasne spremembe v porazdelitvenem volumenu niso opazili.
• Feeling generally weak and tired (temporary anaemia).
• občutek splošne oslabelosti in utrujenosti (začasna anemija).
(platelets between 25.0 and 50.0 x 10
(število trombocitov med 25,0 in 50,0 x 10
If your partner becomes pregnant during your treatment, tell your doctor immediately.
Če med zdravljenjem zanosi vaša partnerka, o tem nemudoma obvestite zdravnika.
• Unusual bruising or bleeding, caused by a decrease in the number of clotting cells in the blood.
• nenavadne podplutbe ali krvavitve, ki nastanejo zaradi zmanjšanja števila celic za strjevanje krvi.
Maidenhead SL6 6RJ
SL6 6RJ
Further management should be as clinically indicated or as recommended by the national poisons centre, where available.
Kjer je možno, bi moralo biti nadaljne ravnanje klinično indicirano ali priporočeno s strani nacionalnega centra za zastrupitve.
Among all patients treated in clinical studies (including both those with severe neutropenia and those who did not develop severe neutropenia), 11 % (4 % of courses) developed fever and 26 % (9 % of courses) developed infection.
Med vsemi bolniki, ki so jih zdravili v kliničnih študijah (vključno s tistimi, ki so imeli hudo nevtropenijo, in tistimi, pri katerih se huda nevtropenija ni pojavila) jih je imelo 11 % (4 % ciklusov zdravljenja) zvišano telesno temperaturo in 26 % (9 % ciklusov zdravljenja) okužbe.
If well tolerated, treatment may continue until disease progression (see sections 4.8 and 5.1).
Če bolnik dobro prenaša zdravljenje, lahko s to shemo nadaljujete, dokler bolezen ne napreduje (glejte poglavji 4.8 in 5.1).
There is no known antidote for topotecan overdose.
Ni znanega antidota za preveliko odmerjanje topotekana.
Each vial contains 4 ml of concentrate.
Vsaka viala vsebuje po 4 ml koncentrata.
This increase is considered unlikely to be of clinical relevance.
Verjetnost, da bi bilo to povečanje klinično pomembno, pa je majhna.
In a population study, a number of factors including age, weight and ascites had no significant effect on clearance of total topotecan (active and inactive form).
V populacijski študiji številni različni dejavniki, na primer starost, telesna masa in ascites, niso pomembno vplivali na očistek celotnega topotekana (aktivne in neaktivne oblike).
Adverse reactions are listed below by system organ class and absolute frequency (all reported events).
Spodaj navedeni neželeni učinki so razvrščeni po organskih sistemih in po absolutni pogostnosti (glede na vse prijavljene dogodke).
As would be expected, patients with poor performance status (PS>1) have a lower response rate and an increased incidence of complications such as fever, infection and sepsis (see section 4.8).
Kot je mogoče pričakovati, se bolniki s slabšo telesno zmogljivostjo(PS > 1) slabše odzivajo na zdravilo in imajo večjo incidenco zapletov, kot so zvišana telesna temperatura, okužbe in sepsa (glejte poglavje 4.8).
In vitro, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A or CYP4A, nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase.
In vitro topotekan ni zaviral delovanja človeških izoencimov citokroma P450 (CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A ali CYP4A) niti človeških citosolskih encimov dihidropirimidin oksidaze ali ksantin oksidaze.
Accurate assessment of performance status at the time therapy is given is important, to ensure that patients have not deteriorated to PS 3.
Pomembna je pravilna ocena bolnikovega stanja na začetku zdravljenja in treba je paziti, da se mu stanje ne poslabša na 3. stopnjo.
Comparison of pharmacokinetic parameters did not suggest any change in pharmacokinetics over the 5 days of dosing.
Primerjava farmakokinetičnih parametrov ni pokazala nobenih sprememb v farmakokinetiki v času 5 dni uporabe topotekana.
− Personnel should be trained to prepare and administer the medicinal product.
− Osebje mora biti usposobljeno za pripravo in dajanje zdravila.
− Severe hypersensitivity to the active substance or to any of the excipients.
− huda preobčutljivost na učinkovino ali katerokoli pomožno snov,
Severe neutropenia lasted beyond seven days in 11 % of courses overall.
Huda nevtropenija je trajala več kot sedem dni pri 11 % vseh ciklusov zdravljenja.
• advanced cervical cancer if surgery or radiotherapy treatment is not possible.
• napredovalega raka materničnega vratu, če zdravljenje s kirurškim posegom ali obsevanjem ni mogoče.
Concentrate for solution for infusion (sterile concentrate).
Koncentrat za raztopino za infundiranje (sterilni koncentrat)
topotecan was discontinued if the dose had been reduced to 1.0 mg/m 2/day and a further dose reduction was required to manage adverse effects.
kliničnih preskušanjih so topotekan ukinili, če je bil odmerek že zmanjšan na 1,0 mg/m 2/dan in bi bilo za odpravo neželenih učinkov potrebno dodatno zmanjšanje odmerka.
Metabolism accounts for <10% of the elimination of topotecan.
Presnova predstavlja < 10 % izločanja topotekana.
In patients presenting with fever, neutropenia and a compatible pattern of abdominal pain, the possibility of neutropenic colitis should be considered.
Pri bolnikih z zvišano telesno temperaturo, nevtropenijo in ustreznim vzorcem trebušnih bolečin je treba pomisliti na možnost nevtropeničnega kolitisa.
Anti-tumour activity was demonstrated primarily in patients with neuroblastoma.
Protitumorsko delovanje topotekana je bilo dokazano predvsem pri bolnikih z nevroblastomom.
Other severe events that were recorded as related or possibly related to topotecan treatment were anorexia (12 %), malaise (3 %) and hyperbilirubinaemia (1 %).
Drugi močno izraženi neželeni dogodki, ki so jih ocenili kot posledico ali možno posledico zdravljenja s topotekanom, so bili anoreksija (12 %), slabo počutje (3 %) in hiperbilirubinemija (1 %).
Overdoses have been reported in patients being treated with intravenous topotecan (up to 10 fold of the recommended dose) and topotecan capsules (up to 5 fold of the recommended dose).
Poročali so o prevelikih odmerjanjih pri pacientih, ki so bili zdravljeni z intravenskim topotekanom (do 10-kratni priporočeni odmerek) in topotekan kapsulami (do 5-kratni priporočeni odmerek).
• Staff handling this medicinal product should wear adequate protective clothing including mask, goggles and gloves.
• Osebje, ki ravna s tem zdravilom, mora nositi ustrezno zaščitno obleko, vključno z masko, očali in rokavicami.
Median time to onset of severe neutropenia was nine days and the median duration was seven days.
Mediana vrednost časa do začetka hude nevtropenije je bila devet dni, mediana vrednost trajanja nevtropenije pa sedem dni.
Standard oncology practice for the management of neutropenia is either to administer topotecan with other medicinal products (e.g. G-CSF) or to reduce the dose to maintain neutrophil counts.
Običajna onkološka praksa pri zdravljenju nevtropenije je bodisi kombiniranje topotekana z drugimi zdravili (npr. G-CSF) ali pa zadostno zmanjšanje odmerka, da se ohranja potrebno število nevtrofilcev.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2°C to 8°C, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Če ni uporabljeno takoj, je za čas njegovega shranjevanja med uporabo in pogoje shranjevanja pred uporabo odgovoren sam uporabnik in naj običajno ne bi presegli 24 ur pri temperaturi 2 °C do 8 °C, razen če sta rekonstutucija in redčenje zdravila potekala v nadzorovanih in validiranih aseptičnih pogojih.
Do not use Topotecan Hospira after the expiry date stated on the vial and carton after EXP.
Zdravila Topotecan Hospira ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na viali in škatli poleg oznake EXP.
An N-desmethyl metabolite, which was shown to have similar or less activity than the parent in a cell-based assay, was found in urine, plasma and faeces.
N-desmetilni presnovek, za katerega je celični test dokazal, da ima podobno ali manjšo aktivnost od matične spojine, so odkrili v seču, plazmi in blatu.
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C under normal light conditions and at 2°C -8°C when protected from light.
Kemična in fizikalna stabilnost zdravila med uporabo je bila dokazana za čas 24 ur pri temperaturi 25 °C v pogojih normalne osvetlitve ter pri temperaturi od 2 °C do 8 °C, kadar je zdravilo zaščiteno pred svetlobo.
Your dose of Topotecan Hospira may need to be adjusted.
Odmerek zdravila Topotrcan Hospira bo morda treba prilagoditi.
Topotecan Hospira is a yellow/yellow green solution.
Zdravilo Topotecan Hospira je rumena ali rumenkasto zelena raztopina.
Topotecan must be reconstituted and further diluted before use (see section 6.6).
Pred uporabo je treba topotekan rekonstituirati in nato še dodatno razredčiti (glejte poglavje 6.6).
In clinical studies, rash was reported in 4 % of patients and pruritus in 1.5 % of patients.
V kliničnih študijah so o izpuščaju poročali pri 4 % bolnikov in o pruritusu pri 1,5 % bolnikov.
• Mild pain and inflammation at the site of injection.
• blage bolečine in vnetje na mestu infundiranja,
• Pregnant staff should be excluded from working with this medicinal product.
• Nosečnice ne smejo delati s tem zdravilom.
• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).
• bolnikih z relapsom drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve izbire ni primerno (glejte poglavje 5.1).
Total or pronounced alopecia was observed in 30 % of patients and partial alopecia in 15 % of patients.
Popolna ali izrazita alopecija se je pojavila pri 30 % bolnikov, delna pa pri 15% bolnikov.
Topotecan was also evaluated in the paediatric population; however, only limited data on efficacy and safety are available.
Uporabo topotekana so ovrednotili tudi pri otrocih, vendar je podatkov o njegovi učinkovitosti in varnosti za otroke malo.
− Personnel handling this medicinal product should wear protective clothing including mask, goggles and gloves.
− Osebje, ki ravna s tem zdravilom, mora nositi ustrezno zaščitno obleko, vključno z masko, očali in rokavicami.
Tell your doctor if you are taking, have recently taken, or might take any other medicines, including any herbal products or medicines obtained without a prescription.
Druga zdravila in zdravilo Topotecan Hospira Obvestite svojega zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo, kar velja tudi za vse zeliščne izdelke in za zdravila, ki ste jih dobili brez recepta.
• Inflammation and ulcers of the mouth, tongue or gums.
• vnetje in razjede v ustih, na jeziku ali na dlesnih,
• Severe allergic or anaphylactic reactions.
• hude alergijske ali anafilaktične reakcije,
As with other cytotoxic medicinal products, topotecan can cause severe myelosuppression.
Kakor druga citotoksična zdravila lahko tudi topotekan povzroči hudo mielosupresijo.
One Phase II study (Study 065) and one Phase III study (Study 396) were conducted to evaluate the efficacy of oral topotecan versus intravenous topotecan in patients who had relapsed ≥90 days after completion of one prior regimen of chemotherapy (see Table 1).
Opravljena je bila ena študija 2. faze (Študija 065) in ena študija 3. faze (Študija 396) za oceno učinkovitosti peroralnega topotekana v primerjavi z intravenskim topotekanom pri bolnikih, ki so imeli ponovitev bolezni ≥ 90 dni po zaključku ene predhodne sheme kemoterapije (glejte preglednico 1).
There is little or no accumulation of topotecan with repeated daily dosing and there is no evidence of a change in the pharmacokinetics after multiple doses.
Pri večkratni vsakodnevni uporabi se topotekan kopiči le malo ali sploh ne in ni nobenih dokazov, da bi se njegova farmakokinetika spremenila po večkratnem odmerjanju.
• Staff should be adequately trained in the preparation, administration and disposal of cytotoxics
• Osebje mora biti ustrezno usposobljeno za pripravo, dajanje in odstranjevanje citotoksičnih zdravil.
However, as with other cytotoxic medicinal products, topotecan is genotoxic and effects on fertility, including male fertility, cannot be excluded.
Ker pa je topotekan - tako kot druga citotoksična zdravila - genotoksičen, ni mogoče izključiti učinkov na plodnost, vključno s plodnostjo samcev.
The second study included a dose range of 2.0 to 5.2 mg/m2 in children (n = 8), adolescents (n = 3), and young adults (n = 3) with leukaemia.
V drugi študiji pa so uporabili razpon odmerkov od 2,0 to 5,2 mg/m2 pri otrocih (n = 8), mladostnikih (n = 3) in mlajših odraslih (n = 3) z levkemijo.
Topotecan should only be administered under the supervision of a physician experienced in the use of chemotherapy (see section 6.6).
Uporaba topotekana naj vedno poteka pod nadzorom izkušenega zdravnika s področja kemoterapije (glejte poglavje 6.6).
These data should be evaluated in the context of the overall safety profile of the medicinal product, in particular of the significant haematological toxicity (see section 4.8).
Pri vrednotenju teh podatkov je treba upoštevati vsa dejstva o varnosti zdravila; zlasti pomembne oblike hematološke toksičnosti (glejte poglavje 4.8).
The topotecan-O-glucuronide and N-desmethyl topotecan-O-glucuronide in the urine were < 2.0 %.
Topotekan-O-glukuronid in N-desmetil topotekan-O-glukuronid sta navzoča v seču v manj kot 2,0 %.
Frequently reported non-haematological effects were gastrointestinal, such as nausea (52 %), vomiting (32 %), diarrhoea (18 %), constipation (9 %) and mucositis (14 %).
Med pogosteje prijavljenimi nehematološkimi učinki so bilegastrointestinalne težave, kot so navzea (52 %), bruhanje (32 %), diareja (18 %), zaprtje (9 %) in mukozitis (14 %).
Preclinical studies indicate plasma protein binding of topotecan is low (35%) and distribution between blood cells and plasma was fairly homogeneous.
Predklinične študije kažejo, da se topotekan le malo veže na plazemske beljakovine (35 %) in da se precej enakomerno porazdeli med krvnimi celicami in plazmo.
• Allergic or hypersensitivity reactions (including rash).
• alergijske ali preobčutljivostne reakcije (vključno z izpuščajem),
Although it is not known whether topotecan is excreted in human breast milk, breast-feeding should be discontinued at the start of therapy.
Čeprav ni znano ali se topotekan izloča v materino mleko, naj matere ob začetku zdravljenja s topotekanom prenehajo dojiti.
The frequencies associated with the haematological and non-haematological adverse events listed below represent the adverse event reports considered to be related/possibly related to topotecan therapy.
Spodaj navedene pogostnosti hematoloških in nehematoloških neželenih dogodkov se nanašajo na poročila o neželenih dogodkih, ki so bili ali bi lahko bili povezani z zdravljenjem s topotekanom.
Underlying risk factors include history of ILD, pulmonary fibrosis, lung cancer, thoracic exposure to radiation and use of pneumotoxic substances and/or colony stimulating factors.
Med osnovne dejavnike tveganja za to sodijo IPB v pretekli anamnezi, pljučna fibroza, pljučni rak, obsevanje prsnega koša in uporaba pnevmotoksičnih snovi in/ali kolonije stimulirajočih faktorjev.
• Signs of infection: Topotecan may reduce the number of white blood cells and lower your resistance to infection.
Topotekan lahko zmanjša število belih krvničk v telesu in vašo odpornost proti okužbam.
Summary of survival, response rate, and time to progression in SCLC patients treated with oral topotecan or intravenous topotecan
Povzetek stopenj preživetja, pogostnosti odziva na zdravljenje in časa do napredovanja bolezni pri bolnikih z drobnoceličnim pljučnim rakom, zdravljenih s peroralnim topotekanom ali intravenskim topotekanom
Resulting from its mechanism of action, topotecan is genotoxic to mammalian cells (mouse lymphoma cells and human lymphocytes) in vitro and mouse bone marrow cells in vivo.
Topotekan je zaradi svojega mehanizma delovanja genotoksičen za celice sesalcev (celice limfoma pri miših in človeške limfocite) in vitro in celice kostnega mozga pri miših in vivo.
Overall recovery of topotecan-related material following five daily doses of topotecan was 71 to 76 % of the administered IV dose.
Skupno izločanje s topotekanom povezanih snovi po dajanju petih dnevnih odmerkov topotekana je znašalo od 71 do 76 % prejetega intravenskega odmerka.
When given in combination with cisplatin (cisplatin day 1, topotecan days 1 to 5), the clearance of topotecan was reduced on day 5 compared to day 1 (19.1 l/h/m 2 compared to 21.3 l/h/m 2 [n=9]) (see section 4.5).
Pri dajanju topotekana v kombinaciji s cisplatinom (cisplatin 1. dan, topotekan od 1. do 5. dne) je bil 5. dan očistek topotekana manjši kot 1. dan (19,1 l/uro/m 2 v primerjavi s 21,3 l/uro/m 2 [n = 9]) (glejte poglavje 4.5).
Median survival (weeks) (95% CI)
Mediana vrednost preživetja (tedni) (95 % IZ)
In reproductive toxicity studies with topotecan in rats there was no effect on male or female fertility; however, in females super-ovulation and slightly increased pre-implantation loss were observed.
V študijah reproduktivne toksičnosti pri podganah topotekan ni vplival na plodnost samcev ali samic; so pa pri samicah opazili superovulacijo in rahel porast predimplantacijskih izgub.
Limited data indicate that the dose should be reduced in patients with moderate renal impairment.
Malo podatkov, ki so na voljo, kažejo, da je treba odmerek zdravila zmanjšati pri bolnikih z zmerno ledvično okvaro.
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability.
Pri sočasni uporabi topotekana z drugimi zdravili za kemoterapijo je lahko potrebno zmanjšanje odmerka vsakega od zdravil zaradi boljšega prenašanja terapije.
This should be taken into account when prescribing Topotecan Hospira, e.g. if patients at increased risk of tumour bleeds are considered for therapy.
To morate upoštevati pri predpisovanju zdravila Topotekan Hospira, na primer pri bolnikih z večjim tveganjem za krvavitve iz tumorja.
Median survivals for the two groups were 25.0 and 24.7 weeks, respectively.
Mediana vrednost časa preživetja bolnikov v prvi skupini je znašala 25,0 tednov, v drugi pa 24,7 tedna.
How topotecan is given A doctor or nurse will administer topotecan as an infusion into your arm lasting about 30 minutes.
Zdravilo Topotecan Hospira vam bo dal zdravnik ali medicinska sestra v obliki infuzije v roko, ki običajno traja približno 30 minut.
Plasma clearance of total topotecan (active and inactive form) in patients with hepatic impairment only decreased by about 10 % compared with the control group of patients.
Plazemski očistek celotnega topotekana (aktivne in neaktivne oblike) se je pri bolnikih z jetrno okvaro zmanjšal samo za približno 10 % v primerjavi z bolniki iz kontrolne skupine.
If there is lasting irritation, a doctor should be consulted.
Če draženje ne preneha, se je treba posvetovati z zdravnikom.
What you need to know before you are given Topotecan Hospira
Kaj morate vedeti, preden boste prejeli zdravilo Topotecan Hospira
In patients with moderate renal impairment topotecan plasma clearance was reduced to 34 % of the value in control patients.
Pri bolnikih z zmerno ledvično okvaro pa se je plazemski očistek topotekana zmanjšal na 34 % vrednosti od bolnikov v kontrolni skupini.
Median time to onset of severe thrombocytopenia, was day 15 and the median duration was five days.
Mediana vrednost časa do pojava hude trombocitopenije je bila na 15. dan, mediana vrednost trajanja trombocitopenije pa pet dni.
The signs and symptoms observed following overdose were consistent with the known undesirable events associated with topotecan (see section 4.8).
Opazovani znaki in simptomi, ki so jih opažali po prevelikem odmerjanju, so v skladu z znanimi neželenimi učinki topotekana (glejte poglavje 4.8).
This treatment schedule is repeated every 21 days for six courses or until progressive disease.
To shemo zdravljenja ponavljajte na vsakih 21 dni za skupaj šest ciklusov ali dokler bolezen ne napreduje.
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease.
Topotekan v kombinaciji s cisplatinom je indiciran pri bolnicah s ponovitvijo karcinoma materničnega vratu po radioterapiji in pri bolnicah s stadijem bolezni IVB.
In a population study using the intravenous route, the co-administration of granisetron, ondansetron, morphine or corticosteroids did not appear to have a significant effect on the pharmacokinetics of total topotecan (active and inactive form).
V populacijski študiji intravenske aplikacije niso zasledili, da bi sočasno dajanje granisetrona, ondansetrona, morfina ali kortikosteroidov bistveno vplivalo na farmakokinetiko celotne količine topotekana (aktivne in neaktivne oblike).
In patients refractory to or relapsing within 3 months after cisplatin therapy (n = 186), the response rate was 10 %.
Pri bolnicah, ki se jim je bolezen kljub zdravljenju s cisplatinom ponovila v roku 3 mesecev, ali ki se niso odzvale na zdravilo (n = 186), pa je bila odzivnost 10 %.
In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose-limiting toxicity of topotecan monotherapy was found to be haematological.
V študijah za določitev odmerka, v katerih je sodelovalo 523 bolnic s ponovitvijo (relapsom) raka jajčnikov in 631 bolnikov s ponovitvijo drobnoceličnega pljučnega raka, so ugotovili, da je pri monoterapiji s topotekanom toksičnost, ki omejuje njegov odmerek, hematološka.
• All items used in the preparation, administration, and cleaning of the medicinal product, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration.
• Vse predmete, ki so bili uporabljeni pri pripravi, dajanju in čiščenju zdravila, vključno z rokavicami, morate odlagati v vreče za sežig nevarnih odpadkov pri visoki temperaturi, tekoče odpadke pa lahko sperete z veliko količino vode.